Ten cases of advanced squamous cell carcinoma of the skin in albinos, treated by radiotherapy from 1973 to 1979 at the Muhimbili Medical Center of Dar-es-Salaam, have been reviewed. Age, sex, duration of symptoms, anatomic distribution, stage of disease, and treatment are reviewed. The relationship between albinism, sunlight, and skin cancer is discussed and a practical program of prevention is suggested. Advanced carcinoma of skin in albinos may be managed successfully with judicious radiation therapy. Excellent objective responses have been noted. No assessment of long-term control is made due to poor follow-up of patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2552804 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Actionable Gene Alterations Identified in Patients With Malignant Melanoma by Targeted Sequencing in Japan.
JCO Precis Oncol
January 2025
Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan.
Purpose: Precision medicine plays an important role in the treatment of patients with advanced melanoma. Despite its high incidence in White patients, advanced melanoma is rare in Asian countries, hampering prospective clinical trials targeting the Asian population. This retrospective study aimed to elucidate the real-world molecular diagnoses and outcomes of Japanese patients with melanoma using comprehensive genome profiling (CGP).
View Article and Find Full Text PDFDiagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.
J Cell Mol Med
January 2025
Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
This study identifies microRNAs (miRNAs) with significant discriminatory power in distinguishing melanoma from nevus, notably hsa-miR-26a and hsa-miR-211, which have exhibited diagnostic potential with accuracy of 81% and 78% respectively. To enhance diagnostic accuracy, we integrated miRNAs into various machine-learning (ML) models. Incorporating miRNAs with AUC scores above 0.
View Article and Find Full Text PDFKnowledge of the risks of ultraviolet radiation, sun exposure attitudes and practices among Lebanese university students.
Prev Med Rep
November 2024
Higher Institute of Public Health, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
Background: Exposure to Ultraviolet radiation (UVR) is a major risk factor for skin cancer. Data about UVR risk knowledge and exposure behaviors in the Lebanese population are scarce.
Aim: To evaluate the association between UVR risks knowledge, attitudes, and behaviors among Lebanese university students in the aim of promoting primary prevention of skin cancer.
A novel surgical technique of use of the Goligher self-retaining retractor for microvascular anastomosis in reconstruction after minimally invasive mastectomy.
Gland Surg
December 2024
Department of Plastic, Reconstructive and Aesthetic Surgery, Sengkang General Hospital, Singapore, Singapore.
In recent years, minimally invasive breast surgery (MIBS) has revolutionized breast cancer treatment, allowing for preservation of aesthetic outcomes while ensuring oncological safety. However, this has created a new challenge in maintaining optimal visualization and dexterity during microvascular anastomosis which is critical for successful autologous tissue reconstruction. Traditional retractors often limit maneuverability, potentially impacting the outcomes of anastomotic procedures.
View Article and Find Full Text PDFBosutinib for the Treatment of CML-Using it Safely: a Podcast.
Target Oncol
January 2025
Division of Hematology and SCT, Georgia Cancer Centre, Augusta, GA, USA.
Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) approved for use in patients with newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase (CP) chronic myeloid leukemia (CML), as well as Ph-positive CP, accelerated phase, or blast phase (with chemotherapy) CML resistant or intolerant to prior therapy. Clinical trials have shown bosutinib is effective as first-line therapy for patients with CML as well as in later lines of therapy after prior TKI failure. Bosutinib has an established safety profile; however, as with all TKIs approved for the treatment of CML, there are adverse events (AEs) that require management.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!